R&D Q4 Clinical trials round-up: October to December 2025 We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.
News CDC signs off on advice ending universal hepatitis B jabs Overturning decades of advice, the CDC has said it no longer recommends that all US newborns receive a hepatitis B vaccine.
News CHMP decision levels the playing field for GSK's RSV jab GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.
News Are RSV shots next in line for restrictions in the US? After pushing for restrictions on vaccines for COVID-19 and hepatitis B, the Trump administration seems to be turning its attention to RSV shots.
News GSK pumps £45m into antimicrobial resistance projects GSK has revealed the six projects it will fund with the Fleming Initiative on antimicrobial resistance, set up with Imperial College London last year.
News Update: MSD's $9.2bn deal for flu biotech Cidara confirmed MSD has signed a $9.2 billion takeover deal for Cidara that will bolt on a universal flu prevention candidate in phase 3.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
